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a b s t r a c t
Intravascular large B cell lymphoma (IVBCL) is a rare type of extranodal large B cell lymphoma
characterized by selective growth of lymphoma cells within the microvasculature. We present an
illustrative case of intravascular B cell lymphoma suspected by the presence of a very small monoclonal B
cell population identiﬁed by immunophenotype and polymerase chain reaction in bone marrow.
The diagnosis was conﬁrmed by skin biopsy.
& 2013 The Authors. Published by Elsevier Ltd.
1. Introduction
Intravascular large B cell lymphoma (IVBCL) is a rare type of
extranodal large B cell lymphoma characterized by selective
growth of lymphoma cells within the microvasculature. We pre-
sent an illustrative case of IVBCL suspected by the presence of a
very small monoclonal B cell population identiﬁed by immuno-
phenotype and polymerase chain reaction in bone marrow. The
diagnosis was conﬁrmed by skin biopsy.
A 72 year-old man was referred to our Hematology service with
a history of four months of recurrent fevers, sweats, weight loss,
headache, proximal limb girdle pain and mild cough. Physical
examination was normal. He had no neurological deﬁcit, and
cardiovascular, respiratory and abdominal examinations disclosed
no signiﬁcant abnormalities. On laboratory analysis creatinine,
alanine aminotransferase, aspartate aminotransferase and immu-
noglobulin levels were within normal range. However, lactate
dehydrogenase 901 UI/L (reference range 230–480 UI/L), gamma-
glutamyl transferase 210 UI/L (reference range 10–71 UI/L), Beta-2
microglobulin 4.1 mg/L (reference range 1.1–2.5) and reactive C
protein 219 mg/L (reference range 0–10 mg/L) were raised. He also
had anemia (Hb 8.4 g/dL) and a leukocyte count of 10.900/μl with
normal differential count; platelet count was 304,000/μl. Auto-
immunity was negative. Blood, sputum, synovial ﬂuid, bone
marrow, urine and stool cultures, serological determinations and
cultures for various microorganisms (Mycobacterium tuberculosis
(Bone Marrow and sputum culture), Leishmania sp (bone marrow
culture), Brucella sp, Syphilis, Toxoplasma gondii, human immuno-
deﬁciency virus, Hepatitis B virus, Hepatitis C virus, Epstein Barr virus
and Cytomegalovirus) gave repeated negative results.
Polymyalgia rheumatica and temporal arteritis were suspected,
and glucocorticoids were administered, leading to some improve-
ment in the patient0s symptoms. However, a temporal artery
biopsy yielded no signiﬁcant ﬁndings.
Since the patient still had fever of unknown origin and
headache, a computer tomography (CT) and a cranial MRI were
performed.
Whole-body CT only showed mild splenomegaly (14 cm) and
an enlarged iliac lymph node (1.53 cm). Cranial MR yielded no
speciﬁc ﬁndings.
To check for a possible tumor, Positron emission tomography
(PET-CT) was performed. PET-CT showed increased FDG uptake in
the adrenals (Suv max 6.7) and spleen (Suv max 3.1). A lympho-
proliferative disorder was suspected and a bone marrow biopsy/
aspiration was performed. Examination of a bone marrow biopsy
specimen should rule out the possibility of macroscopic inﬁltration
by lymphoma or leukemia. However, inﬁltration of 2% of monoclonal
B cells was detected by immunophenotypic analysis in bone marrow.
The neoplastic cells expressed lambda chain, CD19þ , CD20þ ,
CD11cþ , CD79bþ , CD27þ , CD5þ , CD43þ , IgMþ , BCL-2þ ,
CD44þ and CD22þ , CD103 , CD25 , CD38 , Cyclin-D1 negative,
CD23 , CD123 , FMC7 and CD34 . Cytogenetic analysis
revealed a normal 46 XY karyotype, and FISH analyses were negative
for BCL-1, BCL-2, BCL-6. Polymerase chain reaction (PCR)
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demonstrated B cell clonality (CDR2 and CDR3). Demonstration of
immunoglobulin gene rearrangement by PCR in the histological
negative bone marrow sample suggested the presence of intravas-
cular lymphoma, and a decision was made to repeat PET-CT and
perform a biopsy in any organ with increased FDG-uptake.
In the meantime, the patient was given Rituximab. He received
375 mg/m2 of Rituximab per week, but after the third dose the
patient rapidly developed shock and abdominal pain. With the
suspicion of septic shock, the patient received empirical antibiotic
treatment with Meropenem and Vancomycin. Despite aggressive
treatment in the intensive care unit his condition deteriorated
progressively. At this stage, violaceous skin lesions appeared on his
back and shoulders.
Biopsies of skin lesions were performed. Given the strong suspicion
of intravascular lymphoma, the patient agreed to receive treatment
with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
(CHOP) without histological conﬁrmation. After CHOP treatment the
patient developed a myocardial infarction and heart failure despite of
having a previously normal left ventricular ejection fraction. Skin
biopsies conﬁrmed the clinical suspicion of intravascular B cell
lymphoma (Fig. 1). B cell clonality was demonstrated in both skin
and bone marrow by PCR, immunophenotypic analysis and/or immu-
nostaining pattern. The patient0s clinical condition progressively
improved. We decided to change the chemotherapy regimen to avoid
anthracyclins and the patient received four cycles of Rituximab–
Gemcitabine–Oxaliplatin (R-GEMOX) with a partial response and
improvement in cardiac function, which returned to normal. For this
reason we continued the treatment with seven cycles of R-CHOP.
At present, the patient is in complete remission according to PET-CT,
and random skin biopsy; however, persistent bone marrow minimal
residual disease (MRDþ) was detected by immunophenotypic
analysis in June 2013. The patient is receiving Rituximab as main-
tenance in an attempt to eradicate the MRDþ and prevent relapse.
2. Discussion
The clinical diagnosis of IVBCL may be difﬁcult, and in several
reported cases the diagnosis has been made at autopsy [1–3]. In this
case, intravascular B cell lymphoma was suspected because of the
presence of a very small monoclonal B cell population indentiﬁed by
immunophenotype and polymerase chain reaction in bone marrow
[4] and then conﬁrmed by skin biopsy. Patients can present with a
confusing complex that reﬂects organ dysfunction secondary to
vascular obstruction or systemic symptoms such as unexplained
fever [5–7]. Two major patterns of clinical presentation have been
recognized a Western form characterized by symptoms related to
involvement of the central nervous system and skin [8–14] and an
Asian variant in which the patients present with multiorgan failure,
hepatosplenomegaly, pancytopenia and hemophagocytic syndrome
[15]. However, the lymphoma is usually widely disseminated in
extranodal sites including bone marrow, spleen, liver, lungs, skin,
nervous system and rarely in blood [14,16–23]. The diagnosis of
IVBCL is made by demonstrating the presence of large lymphoma
cells within small to medium blood vessels [24]. As far as diagnosis is
concerned, biopsies of diseased skin or random biopsies of “normal”
skin without any obvious abnormality may be diagnostic [25]. If this
does not yield a diagnosis, biopsy of other sites of suspected
involvement may be undertaken in the appropriate clinical setting.
Despite a relatively high proportion of false negatives, experts
recommend staging work up with contrasted whole-body compu-
terized tomography scan, contrasted whole-brain magnetic reso-
nance imaging, peripheral blood smear, cerebrospinal ﬂuid cytology
and biochemical examination and bone marrow biopsy [24]. [18F]
FDG-positron emission tomography may also be useful for the early
diagnosis of IVBCL and can guide biopsies of affected organs [26–29].
Accurate and timely diagnosis of IVBCL is still a problematic issue,
and many cases are diagnosed at autopsy. However, in recent years,
the heightened awareness of IVBCL with appropriate investigations
has resulted in more patients being diagnosed during life.
Delays in diagnosis due to the subtlety and focal nature of the
intravascular inﬁltrates often lead to a terminal disease with death
before chemotherapy is initiated. R-CHOP plus CNS prophylaxis is
the treatment of choice in patients [30,31] without nervous system
involvement. CNS involvement and recurrence is still challenging
despite the improvement in clinical outcomes induced by Ritux-
imab plus chemotherapy.
CNS prophylaxis is strongly recommended because CNS recur-
rence at 3 years is still as high as 25% [32,33]. The fact that several
patients have CNS involvement at diagnosis or relapse supports
the recommendation to use chemotherapy combinations contain-
ing drugs with high CNS bioavailability such as high dose Methro-
trexate and high dose Cytarabine in these patients.
Even though high-dose chemotherapy supported by autologous
stem cell support (HDC/ASCT) seems to be a useful option in
younger patients with unfavorable features [34], the main indica-
tion for HDC/ASCT remains consolidation in chemosensitive relap-
sing disease, as is the case for other diffuse large B cell lymphomas
in a small proportion of patients.
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